<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786871</article-id><article-id pub-id-type="pii">S2405-8440(25)00301-9</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2025.e41921</article-id><article-id pub-id-type="publisher-id">e41921</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Thyroid hormones and neurological impairments during the first two days after stroke: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Akhoundzadeh</surname><given-names>Kobra</given-names></name><email>mehr2257@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Zarvani</surname><given-names>Ashraf</given-names></name><email>dr.azarvani@gmail.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Mohajerani</surname><given-names>Fatemeh</given-names></name><email>fmohajerani7@gmail.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Shafia</surname><given-names>Sakineh</given-names></name><email>srshafia@yahoo.com</email><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff1"><label>a</label>Department of Physiology, Qom University of Medical Sciences, Qom, Iran</aff><aff id="aff2"><label>b</label>Department of Neurology, Mazandaran University of Medical Sciences, Sari, Iran</aff><aff id="aff3"><label>c</label>Department of Neurology, Yasuj University of Medical Sciences, Yasuj, Iran</aff><aff id="aff4"><label>d</label>Immunogenetics Research Center, Department of Physiology, Mazandaran University of Medical Sciences, Sari, Iran</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. <email>srshafia@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>11</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>11</day><month>1</month><year>2025</year></pub-date><volume>11</volume><issue>2</issue><elocation-id>e41921</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Despite plenty of studies on the change in thyroid hormones after stroke, there is still no consensus for a comprehensive conclusion and clinical application. This pilot study aimed to investigate the change in thyroid hormones and its association with neurological impairments during the first two days after the stroke. This was a cross-sectional descriptive and analytical study. Neurological deficits were assessed using the National Institutes of Health Stroke Scale (NIHSS). In addition, blood samples were collected for TSH, T<sub>3,</sub> and T<sub>4</sub>. P value&#x000a0;&#x0003c;&#x000a0;0.05 was considered significant. Fifty patients (42&#x000a0;% men) with a mean age of 69.73 (SD&#x000a0;&#x000b1;&#x000a0;12.31) were included. The majority of patients had a high level of TSH and T<sub>4</sub>, and a normal level of T<sub>3</sub> on the first and second days of hospitalization. 33.3 and 20.9 percent of patients had NIHSS scores &#x0003e;10 on the first and second day respectively. According to the multivariate analysis, high T<sub>4</sub> hormone was as a predictor of NIHSS score &#x0003e;10. There was no association between thyroid hormones and NIHSS at the admission. In addition, there was no relationship between thyroid hormones and TSH on the second day. According to the results, stroke affects the levels of thyroid hormones and the pituitary&#x02013;thyroid axis. Because of the diversity in results of existing studies, further clinical research with the same methodology and data analysis is needed to find consistent results on the association between thyroid hormones and neurological impairments. Monitoring thyroid status in stroke patients may be recommendable.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">The levels of TSH and T<sub>4</sub> hormones are altered after stroke.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">High T<sub>4</sub> hormone could be a predictor of moderate to severe strokes.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">The stroke probably affects the negative feedback of the pituitary-thyroid axis.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Thyroid hormone</kwd><kwd>Neurological impairments</kwd><kwd>Stroke</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0025">Stroke remains a world challenge, and therefore more effective strategies for preventing and managing stroke are still required [<xref rid="bib1" ref-type="bibr">1</xref>]. Although plenty of studies have been done on the change in thyroid hormones after stroke, there is still no consensus for a comprehensive conclusion and clinical application [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>]. Non-thyroidal illness syndrome (NTIS) and low T<sub>3</sub> syndrome are some definitions applied for the change in thyroid hormones after illnesses such as stroke [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. NTIS described the abnormality of thyroid hormones, particularly T<sub>3</sub> following illness without thyroid dysfunction [<xref rid="bib5" ref-type="bibr">5</xref>]. According to the evidence, T<sub>3</sub> can be considered as a prognostic biomarker in patients with ischemic stroke [<xref rid="bib7" ref-type="bibr">7</xref>]. Besides T<sub>3</sub> and T<sub>4</sub>, TSH is also affected by stroke [<xref rid="bib3" ref-type="bibr">3</xref>]. It seems that TSH alteration after stroke can be related to central hypothyroidism reported in many illness models. Central hypothyroidism is due to diminished hypothalamic TRH in the brain [<xref rid="bib5" ref-type="bibr">5</xref>].</p><p id="p0030">In spite of numerous studies evaluating thyroid hormone change after stroke, it is still unknown whether thyroid hormone alternations have beneficial or harmful effects [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>,<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>]. These ambiguities make thyroid hormone replacement therapy controversial in clinics [<xref rid="bib5" ref-type="bibr">5</xref>]. Also, it is unclear which hormone (T<sub>3</sub> or T<sub>4</sub>) can be suitable to be used [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. Nevertheless, some studies showed therapeutic effects of T<sub>3</sub> and T<sub>4</sub> administration in experimental studies [<xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>].</p><p id="p0035">Some of the mechanisms that have been supposed for beneficial effects of thyroid hormones on stroke include anti-edema action through the inhibition of aquaporin-4 water channel expression [<xref rid="bib16" ref-type="bibr">16</xref>], upregulation of BDNF and GDNF in the hippocampus [<xref rid="bib17" ref-type="bibr">17</xref>], inhibition of apoptosis, and suppression of inflammatory reactions [<xref rid="bib14" ref-type="bibr">14</xref>]. Conversely, according to some studies, hypothyroid animals subjected to cerebral ischemia showed the protective effects of hypothyroidism such as reduced metabolic activity, apoptosis, necrosis, oxidative stress, cell death [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>], and glutamate release [<xref rid="bib20" ref-type="bibr">20</xref>]. Similarly, both negative and positive associations have been shown between thyroid hormones states and post-stroke neurological impairments in human studies [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>].</p><p id="p0040">Taken together the results related to thyroid hormone changes after stroke and the association between thyroid hormone levels and neurological impairments in stroke patients are controversial and not yet useful for clinical application. Also, as far as we found the majority of existing studies assessed thyroid hormone changes on the admission day of the stroke while the peak of many stroke-related changes such as inflammation or cerebral edema is observed on day-2 or later [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]. This pilot study aimed to investigate the change in thyroid hormones and its association with post-stroke neurological impairments during the first two days after stroke.</p></sec><sec id="sec2"><label>2</label><title>Methods and materials</title><p id="p0045">This was a cross-sectional descriptive and analytical study done in the Department of Neurology of Bouali Hospital in Sari affiliated to Mazandaran University of Medical Sciences, Iran. Patients with acute cerebral ischemic stroke signs and symptoms diagnosed by neurologist using clinical assessment and computed tomography (CT) or magnetic resonance imaging (MRI) findings were enrolled in the study. Inclusion criteria were new ischemic stroke patients between 18 and 80 years old and without a history of thyroid abnormality and neurological disorders. Hemorrhagic stroke, death, severe complications (such as severe brain edema, haemorrhagic transformation, cardiac arrest, respiratory failure, etc.), bleeding, a history of thyroid abnormality, and use of thyroxine therapy or antithyroid medication were considered as exclusion criteria. None of the patients underwent thrombolytic therapy. The patients were selected using consecutive sampling method between December 2020 and September 2021. The study was approved by Iran National Committee for Ethics in Biomedical Research (Approval Code: IR.MAZUMS.REC.1398.1098 and IR.MAZUMS.REC.1398.397). All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s). The data were collected anonymously. Neurological deficits were assessed by a neurologist using the National Institutes of Health Stroke Scale (NIHSS) on the admission and the second days of hospitalization (<ext-link ext-link-type="uri" xlink:href="https://www.stroke.nih.gov/documents/NIH_Stroke_Scale_508C.pdf" id="intref0010">https://www.stroke.nih.gov/documents/NIH_Stroke_Scale_508C.pdf</ext-link>). In addition, data on demographic characteristics and the history of hypertension, diabetes, heart disease, atrial fibrillation, stroke, hyperlipidemia,&#x02009;smoking, and alcohol use were collected.</p><p id="p0050">Blood samplings for TSH, total T<sub>3</sub>, and total T<sub>4</sub> were gathered at admission and day 2. The serums were frozen at &#x02212;20C until laboratory measurement. The hormones were measured by enzyme-linked immunosorbent assay (ELISA) kit (Pishtazteb Co. Iran). Normal ranges for TSH, total T<sub>4</sub>, and total T<sub>3</sub> are 1.1&#x02013;1.8 mlU/L, 6.4&#x02013;9.0&#x000a0;&#x003bc;g/dl, and 0.9&#x02013;1.6&#x000a0;ng/ml respectively.</p></sec><sec id="sec3"><label>3</label><title>Statistical analysis</title><p id="p0055">After testing for normality, non-parametric quantitative data were presented as median (IQR) and qualitative data were presented as frequency and percentages. The groups were compared using Wilcoxon test, or chi-square tests. The correlation between non-parametric data was analyzed using Spearman's tests. Binary logistic regression analysis was performed to determine the predictors of moderate to severe neurological deficits. Data were analyzed using SPSS software version 22. P value&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant.</p></sec><sec id="sec4"><label>4</label><title>Results</title><p id="p0060">Fifty patients with available laboratory data and neurological impairment documentation were included, 21 men and 29 women with a mean age of 69.73 (SD&#x000a0;&#x000b1;&#x000a0;12.31). Patient Characteristics are listed in <xref rid="tbl1" ref-type="table">Table 1</xref>.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Characteristics of study patients.</p></caption><alt-text id="alttext0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Variables</th></tr></thead><tbody><tr><td align="left">Age (mean&#x000a0;&#x000b1;&#x000a0;SD)</td><td align="left">69.7&#x000a0;&#x000b1;&#x000a0;12.3</td></tr><tr><td colspan="2" align="left">Sex</td></tr><tr><td align="left">&#x000a0;Female n %</td><td align="left">29 (58 %)</td></tr><tr><td align="left">&#x000a0;Male n %</td><td align="left">21 (42 %)</td></tr><tr><td colspan="2" align="left">History of</td></tr><tr><td align="left">&#x000a0;&#x02009;HTN n %</td><td align="left">33 (78.6 %)</td></tr><tr><td align="left">&#x000a0;&#x02009;Diabetes n %</td><td align="left">21 (51.2 %)</td></tr><tr><td align="left">&#x000a0;&#x02009;Heart disease n %</td><td align="left">18 (38.3 %)</td></tr><tr><td align="left">&#x000a0;Stroke n %</td><td align="left">13 (27.7&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Hyperlipidemia n %</td><td align="left">18 (38.3 %)</td></tr><tr><td align="left">&#x000a0;&#x02009;Atrial fibrillation n %</td><td align="left">4 (8.5 %)</td></tr><tr><td align="left">&#x000a0;&#x02009;Smoking n %</td><td align="left">3 (5.8&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Alcohol n %</td><td align="left">0</td></tr></tbody></table></table-wrap></p><p id="p0065">The frequency and percent of the patients with low, normal, or high levels of TSH and thyroid hormones on the first and second days after stroke are summarized in <xref rid="tbl2" ref-type="table">Table 2</xref>. In addition, this table shows the frequency of patients with minor to moderate stroke or moderate to severe stroke. It is noteworthy that the results showed that 27 (56.3&#x000a0;%) and 33 (68.8&#x000a0;%) patients had a minor stroke (NIHSS&#x02264;8) on the first and second days respectively.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Frequency and percent of low, normal, and high levels of TSH and thyroid hormones, and stroke severity on the first and second days.</p></caption><alt-text id="alttext0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Admission day n %</th><th>Second day n %</th></tr></thead><tbody><tr><td colspan="3" align="left"><bold>TSH</bold></td></tr><tr><td align="left">&#x000a0;&#x0003c;1.1 mlu/l</td><td align="left">11 (22.4&#x000a0;%)</td><td align="left">16 (33.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Normal</td><td align="left">14 (28.6&#x000a0;%)</td><td align="left">13 (27.1&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;1.8 mlu/l</td><td align="left">24 (49&#x000a0;%)</td><td align="left">19 (39.6&#x000a0;%)</td></tr><tr><td colspan="3" align="left"><bold>T</bold><sub><bold>3</bold></sub></td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x000a0;0.9&#x000a0;ng/mL</td><td align="left">3 (6.1&#x000a0;%)</td><td align="left">4 (8.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Normal</td><td align="left">37 (75.5&#x000a0;%)</td><td align="left">35 (72.9&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x000a0;1.6&#x000a0;ng/mL</td><td align="left">9 (18.4&#x000a0;%)</td><td align="left">9 (18.8&#x000a0;%)</td></tr><tr><td colspan="3" align="left"><bold>T</bold><sub><bold>4</bold></sub></td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x000a0;6.4&#x000a0;&#x003bc;g/dl</td><td align="left">0 (0&#x000a0;%)</td><td align="left">1 (2.1&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Normal</td><td align="left">17 (34.7&#x000a0;%)</td><td align="left">18 (37.5&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;9&#x000a0;&#x003bc;g/dl</td><td align="left">32 (65.3&#x000a0;%)</td><td align="left">29 (60.4&#x000a0;%)</td></tr><tr><td colspan="3" align="left"><bold>NIHSS</bold></td></tr><tr><td align="left">&#x000a0;minor to moderate stroke (NIHSS &#x02264;10)</td><td align="left">32 (66.7&#x000a0;%)</td><td align="left">38 (79.2&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;moderate to severe stroke (NIHSS &#x0003e;10)</td><td align="left">16 (33.3&#x000a0;%)</td><td align="left">10 (20.8&#x000a0;%)</td></tr></tbody></table></table-wrap></p><p id="p0070">The Wilcoxon signed-rank test showed no significant differences between T<sub>3</sub>, T<sub>4</sub>, and TSH levels on the first and second days (<xref rid="tbl3" ref-type="table">Table 3</xref>). Although there was no statistically significant difference between the first and second day NIHSS scores, the p-value was near the level of significance (0.052) (<xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Comparison of thyroid hormones, TSH, and NIHSS between the first and second days.</p></caption><alt-text id="alttext0020">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Admission time<break/>Median (IQR)</th><th>Second day<break/>Median (IQR)</th><th>P-value</th></tr></thead><tbody><tr><td align="left"><bold>TSH</bold></td><td align="char">1.8 (1.1&#x02013;2.6)</td><td align="char">1.4 (0.90&#x02013;2.6)</td><td align="char">0.71</td></tr><tr><td align="left"><bold>T</bold><sub><bold>3</bold></sub></td><td align="char">1.5 (1.1&#x02013;1.6)</td><td align="char">1.2(1.1&#x02013;1.5)</td><td align="char">0.44</td></tr><tr><td align="left"><bold>T</bold><sub><bold>4</bold></sub></td><td align="char">9.8 (8&#x02013;10.7)</td><td align="char">9.15 (7.95&#x02013;10.37)</td><td align="char">0.51</td></tr><tr><td align="left"><bold>NIHSS</bold></td><td align="char">8 (5&#x02013;11)</td><td align="char">5 (4&#x02013;9)</td><td align="char">0.052</td></tr></tbody></table></table-wrap></p><p id="p0075"><xref rid="tbl4" ref-type="table">Table 4</xref> presents the associations between thyroid hormones, TSH, and NIHSS analyzed using Spearman's test. There was no relationship between NIHSS and thyroid hormones or TSH. The first-day TSH was correlated with thyroid hormones, while there was no relationship between TSH and thyroid hormones on the second day.<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Associations (correlation coefficient r<sub>s</sub>) between thyroid hormones, TSH, and NIHSS score analyzed using Spearman's test.</p></caption><alt-text id="alttext0025">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="2"/><th colspan="4">First day<hr/></th><th colspan="4">Second day<hr/></th></tr><tr><th>TSH</th><th>T<sub>3</sub></th><th>T<sub>4</sub></th><th>NIHSS</th><th>TSH</th><th>T<sub>3</sub></th><th>T<sub>4</sub></th><th>NIHSS</th></tr></thead><tbody><tr><td rowspan="4" align="left"><bold>First day</bold></td><td align="left"><bold>TSH</bold></td><td align="left">&#x02013;</td><td align="left">&#x02212;0.37&#x02217;&#x02217;</td><td align="left">&#x02212;0.29&#x02217;</td><td align="left">NS</td><td align="left">0.61&#x02217;&#x02217;</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left"><bold>T</bold><sub><bold>3</bold></sub></td><td align="left">&#x02212;0.37&#x02217;&#x02217;</td><td align="left">&#x02013;</td><td align="left">0.28&#x02217;</td><td align="left">NS</td><td align="left">&#x02212;0.30&#x02217;</td><td align="left">0.38&#x02217;&#x02217;</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left"><bold>T</bold><sub><bold>4</bold></sub></td><td align="left">&#x02212;0.29&#x02217;</td><td align="left">0.28&#x02217;</td><td align="left">&#x02013;</td><td align="left">NS</td><td align="left">NS</td><td align="left">0.38&#x02217;&#x02217;</td><td align="left">0.39&#x02217;&#x02217;</td><td align="left">NS</td></tr><tr><td align="left"><bold>NIHSS</bold></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">&#x02013;</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td rowspan="4" align="left"><bold>Second day</bold></td><td align="left"><bold>TSH</bold></td><td align="left">0.61&#x02217;&#x02217;</td><td align="left">&#x02212;0.30&#x02217;</td><td align="left">NS</td><td align="left">NS</td><td align="left">&#x02013;</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td></tr><tr><td align="left"><bold>T</bold><sub><bold>3</bold></sub></td><td align="left">NS</td><td align="left">0.38&#x02217;&#x02217;</td><td align="left">0.38&#x02217;&#x02217;</td><td align="left">NS</td><td align="left">NS</td><td align="left">&#x02013;</td><td align="left">0.49&#x02217;&#x02217;</td><td align="left">NS</td></tr><tr><td align="left"><bold>T</bold><sub><bold>4</bold></sub></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">0.39&#x02217;&#x02217;</td><td align="left">NS</td><td align="left">NS</td><td align="left">0.49&#x02217;&#x02217;</td><td align="left">&#x02013;</td><td align="left">NS</td></tr><tr><td align="left"><bold>NIHSS</bold></td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">NS</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>NS not significant, &#x02217;p&#x000a0;&#x0003c;&#x000a0;0.05; &#x02217;&#x02217;p&#x000a0;&#x0003c;&#x000a0;0.01.</p></fn></table-wrap-foot></table-wrap></p><p id="p0080">The result of univariate and multivariate analysis between thyroid hormone and TSH levels and second-day NIHSS&#x0003e;10 is presented in <xref rid="tbl5" ref-type="table">Table 5</xref>. According to the results of univariate analysis, high TSH and high T<sub>4</sub> on the second day had an association with moderate to severe stroke. However, after multivariate analysis, only high T<sub>4</sub> remained as a predictor of moderate to severe stroke (&#x003b2;&#x000a0;=&#x000a0;&#x02212;2.58, p&#x000a0;=&#x000a0;0.018).<table-wrap position="float" id="tbl5"><label>Table 5</label><caption><p>Univariate and multivariate analysis between thyroid hormone and TSH levels and second-day NIHSS&#x0003e;10. The factors that were found to contribute to the NIHSS in the univariate analysis at P values&#x000a0;&#x0003c;&#x000a0;0.2 were included in the multivariate. For each variable, the odds ratio (OR), and 95&#x000a0;% confidence interval (CI) are given.</p></caption><alt-text id="alttext0030">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="3">Univariate analysis<hr/></th><th colspan="3">Multivariate analysis<hr/></th></tr><tr><th>Odd ratio (OR)</th><th>95&#x000a0;% CI</th><th>P value</th><th>Odd ratio (OR)</th><th>95&#x000a0;% CI</th><th>P value</th></tr></thead><tbody><tr><td align="left"><bold>Age</bold></td><td align="char">1.03</td><td align="char">0.94&#x02013;1.09</td><td align="char">0.401</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Sex</bold></td><td align="char">2.88</td><td align="char">0.69&#x02013;12.07</td><td align="char">0.147</td><td align="char">3.43</td><td align="char">0.39&#x02013;29.95</td><td align="char">0.26</td></tr><tr><td align="left"><bold>HTN</bold></td><td align="char">1.38</td><td align="char">0.275&#x02013;6.92</td><td align="char">0.69</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Diabetes</bold></td><td align="char">1.67</td><td align="char">0.34&#x02013;8.17</td><td align="char">0.53</td><td align="left">&#x02013;</td><td/><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Heart disease</bold></td><td align="char">0.24</td><td align="char">0.51&#x02013;1.13</td><td align="char">0.071</td><td align="char">0.17</td><td align="char">0.022&#x02013;1.26</td><td align="char">0.08</td></tr><tr><td align="left"><bold>Stroke</bold></td><td align="char">0.40</td><td align="char">0.09&#x02013;1.83</td><td align="char">0.29</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Hyperlipidemia</bold></td><td align="char">0.94</td><td align="char">0.07&#x02013;11.97</td><td align="char">0.96</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Atrial fibrillation</bold></td><td align="char">0.71</td><td align="char">0.06&#x02013;7.70</td><td align="char">0.77</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>First day&#x02009;TSH&#x0003e;1.8</bold></td><td align="char">1.11</td><td align="char">0.28&#x02013;4.48</td><td align="char">0.88</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Second day TSH&#x0003e;1.8</bold></td><td align="char">5.06</td><td align="char">1.11&#x02013;23.01</td><td align="char">0.036</td><td align="char">5.01</td><td align="char">0.55&#x02013;45.54</td><td align="char">0.15</td></tr><tr><td align="left"><bold>First day T</bold><sub><bold>3</bold></sub><bold>&#x0003e;1.6</bold></td><td align="char">3.75</td><td align="char">0.87&#x02013;16.22</td><td align="char">0.077</td><td align="char">2.07</td><td align="char">0.23&#x02013;18.74</td><td align="char">0.52</td></tr><tr><td align="left"><bold>Second day T</bold><sub><bold>3</bold></sub><bold>&#x0003e;1.6</bold></td><td align="char">1.24</td><td align="char">0.22&#x02013;6.9</td><td align="char">0.81</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>First day T</bold><sub><bold>4</bold></sub><bold>&#x0003e;9</bold></td><td align="char">0.69</td><td align="char">0.16&#x02013;2.92</td><td align="char">0.62</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>Second day T</bold><sub><bold>4</bold></sub><bold>&#x0003e;9</bold></td><td align="char">5.06</td><td align="char">1.11&#x02013;23.01</td><td align="char">0.036</td><td align="char">13.22</td><td align="char">1.56&#x02013;111.79</td><td align="char">0.018</td></tr></tbody></table></table-wrap></p></sec><sec id="sec5"><label>5</label><title>Discussion</title><p id="p0085">Our main findings were that the majority of patients had high TSH and T<sub>4</sub> levels and a normal T<sub>3</sub> on the admission and second days. High T<sub>4</sub> hormone on the second day was a predictor of moderate to severe strokes (NIHSS &#x0003e;10). There were no negative expected relationships between TSH and thyroid hormones on the second day.</p><p id="p0090">Although existing studies reported low T<sub>3</sub> syndrome after illnesses [<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib23" ref-type="bibr">23</xref>], our study did not show a low T<sub>3</sub> level on the admission day except in 3 patients (6&#x000a0;%), and the median T<sub>3</sub> level remained in the normal range (<xref rid="tbl3" ref-type="table">Table 3</xref>). This discrepancy in results may be because of differences in the severity of illness. In our study the majority of patients were admitted with a minor to moderate stroke (NIHSS score &#x02264;10), and severe stroke (NIHSS&#x0003e;20) was just revealed in 3.8&#x000a0;% of patients (Data was not shown). Accordingly, our finding is in agreement with the literature that reported that the degree of serum total T<sub>3</sub> falls in illness is often proportional to the severity of illness [<xref rid="bib5" ref-type="bibr">5</xref>]. It is stated that in serious illness, low T<sub>3</sub> is a compensatory mechanism to save energy and protein [<xref rid="bib24" ref-type="bibr">24</xref>]. Partly similar to our result, in Chen and colleagues' study mean serum T<sub>3</sub> concentration after stroke remained in the normal range [<xref rid="bib23" ref-type="bibr">23</xref>]. Also, Zhang and colleagues showed that the majority of patients with mild stroke (NIHSS &#x0003c;8) had normal T<sub>3</sub> [<xref rid="bib25" ref-type="bibr">25</xref>].</p><p id="p0095"><xref rid="tbl4" ref-type="table">Table 4</xref>, <xref rid="tbl5" ref-type="table">Table 5</xref> present that there was no association between T<sub>3</sub> and NIHSS. Although the association between low T<sub>3</sub> and stroke severity or neurological deficit following stroke was reported in several studies [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>], and some studies showed an inverse association between low T<sub>3</sub> and post-stroke outcome [<xref rid="bib29" ref-type="bibr">29</xref>], due to the small number of patients with low T<sub>3</sub> levels, we were unable to statistically assess the association between low T<sub>3</sub> levels and stroke severity.</p><p id="p0100">As shown in <xref rid="tbl3" ref-type="table">Table 3</xref>, the median TSH level, especially on the first day, tended to the upper limit, and the majority of patients had a high level of TSH. It is reported that TSH level is suppressed after a moderate to severe illness [<xref rid="bib5" ref-type="bibr">5</xref>], therefore, since in the present study the majority of patients had a minor stroke, TSH suppression was not marked. It is worth mentioning that although, rank Spearman correlation and multivariate analysis did not show a statistically significant relationship between TSH and NIHSS on the second day, based on univariate analysis a high level of TSH was a negative predictor of moderate to severe neurological impairment on the second day (&#x003b2;&#x000a0;=&#x000a0;&#x02212;1.62). O&#x02019; Keefe and colleagues' study reported no association between NIHSS and TSH [<xref rid="bib30" ref-type="bibr">30</xref>], however, in Akhound and colleagues' study, patients with higher levels of serum TSH tended to have a milder stroke [<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib32" ref-type="bibr">32</xref>]. Also, a meta-analysis study showed elevated TSH may correspond to better functional outcomes [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0105">The results of the present study revealed that the T<sub>4</sub> level, especially on the first day, was higher than normal in over 60&#x000a0;% of patients. Partly in harmony with our finding, it is reported that dependent on the methodology, FT<sub>4</sub> may show an increase in an illness of a moderate severity [<xref rid="bib5" ref-type="bibr">5</xref>]. According to some studies, high T<sub>4</sub> levels and low levels of T<sub>3</sub> after stroke may be explained by decreased peripheral conversion of T4 to T3. In addition, the reduction in peripheral conversion is related to disease severity [<xref rid="bib33" ref-type="bibr">33</xref>].</p><p id="p0110">As shown in <xref rid="tbl5" ref-type="table">Table 5</xref>, a high level of T<sub>4</sub> on day 2 was a predictor of moderate to severe neurological deficit. Since the beta coefficient was negative in direction, it indicates that high T<sub>4</sub> was a negative predictor of neurological deficit. After adjustment, none of the other hormones, including T<sub>3</sub>, T<sub>4</sub>, and TSH on the first day, and T<sub>3</sub> and TSH on the second day were the predictor of moderate to severe neurological deficit on day 2. It is mentionable that there was no association between moderate to severe neurological deficit and high level of T<sub>4</sub> on the admission day (data was not shown). The results of the relationship between T<sub>4</sub> and neurological deficit and stroke outcomes are confusing. Many studies showed no significant association between T<sub>4</sub> and neurological deficit [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib25" ref-type="bibr">25</xref>,<xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>] and some revealed that lower T<sub>4</sub> was associated with worse neurological outcomes [<xref rid="bib39" ref-type="bibr">39</xref>]. However, a meta-analysis reported that patients with poor outcomes had significantly higher T<sub>4</sub> levels and lower levels of T<sub>3</sub> [<xref rid="bib2" ref-type="bibr">2</xref>]. Although the exact mechanisms underlying the adverse effects of thyroid hormones on stroke outcomes are not still understood well, a probable mechanism is the excitement of sympathetic nervous system induced by excessive thyroid hormones. The overactivation of the sympathetic nervous system can lead to a severe hypermetabolic response followed by higher production of Reactive Oxygen Species (ROS) and free radicals and cytotoxicity (see the review article by Murolo et al.)[<xref rid="bib40" ref-type="bibr">40</xref>].</p><p id="p0115">It seems that the form of thyroid hormone assessed as free or total hormone may be involved in the variability of the results because it is asserted that the change of free thyroid hormones in illness is more modest than that of total thyroid hormone [<xref rid="bib5" ref-type="bibr">5</xref>]. In the present study, total T<sub>4</sub> was measured owing to more detectable changes, however, the majority of the mentioned studies measured free T<sub>4</sub> [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib29" ref-type="bibr">29</xref>,<xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>]. It is important to mention that in our study, confidence intervals in regression analysis were too wide (<xref rid="tbl5" ref-type="table">Table 5</xref>), which means a greater uncertainty level. Since the present study was a pilot study and the sample size was small, it influenced confidence intervals.</p><p id="p0120">According to the results in <xref rid="tbl3" ref-type="table">Table 3</xref>, although not statistically significant, all parameters including stroke severity score (NIHSS), T<sub>3</sub>, T<sub>4</sub>, and TSH were coordinately higher on the first day than that on the second day. The reduction in T<sub>3</sub>, T<sub>4</sub>, and TSH from the hyper-acute (within 24&#x000a0;h) to acute (3&#x02013;5 days) stages of stroke was also reported in Sidorov and colleague's study [<xref rid="bib26" ref-type="bibr">26</xref>]. Due to the lack of statistically significant results, we cannot draw a conclusion, however, the question arises whether thyroid hormone alterations are affected by stroke severity, or stroke severity is impressed by thyroid hormone alternations.</p><p id="p0125">Another main finding of the present study was that the physiological relationships between TSH and thyroid hormones were preserved on the first day; however, these relationships were not maintained on the second day (<xref rid="tbl4" ref-type="table">Table 4</xref>). In other words, negative feedback of pituitary&#x02013;thyroid axis was not observed on the second day after stroke. Since it is asserted that illnesses could profoundly impress neuroendocrine systems such as the hypothalamic&#x02013;pituitary&#x02013;thyroid (HPT) axis [<xref rid="bib5" ref-type="bibr">5</xref>], disturbance of the relationship between TSH and thyroid hormones may partly be explained. However, it is not clear whether hypothalamic&#x02013;pituitary&#x02013;thyroid axis changes after illnesses are a compensating or detrimental response [<xref rid="bib5" ref-type="bibr">5</xref>].</p><p id="p0130">The studies of the relationship between thyroid hormones and stroke severity and neurological impairment showed different findings. Some factors that may contribute the diverse findings include different assessment scales for neurological impairment (NIHSS, mRs, Scandinavian Stroke Scale, etc.), different categorizations of neurological impairment (minor, mind, moderate, and severe), the form of thyroid hormone (total, free), the time of assessment, and small sample size. Whether correcting thyroid profile with hormone supplementation or antagonism may lead to improved outcomes will require large, prospective, interventional studies. Overall, the relationship between thyroid hormones and strokes seems to be complicated and requires further well-designed investigations.</p><p id="p0135">Lastly, it needs to be mentioned that the data on self-reported smoking and alcohol use (<xref rid="tbl1" ref-type="table">Table 1</xref>) seems to be not valid due to patients' reluctant to report, as was also shown in other studies [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>].</p></sec><sec id="sec6"><label>6</label><title>Limitations and recommendations</title><p id="p0140">Further studies with a well-designed method and increased number of patients should be done to achieve more reliable results. In addition, assessment of hormone levels and neurological impairments over multiple time points is recommended to find their association over time. The lack of neurological outcome assessments at discharge or long time assessments was a limitation of this study.</p></sec><sec id="sec7"><label>7</label><title>Conclusion</title><p id="p0145">According to the results of the present study, stroke affects the TSH and T4 levels, and the negative feedback of the pituitary&#x02013;thyroid axis. Also, T<sub>4</sub> can be suggested as a predictor of moderate to severe stroke. However, the T<sub>3</sub> level was maintained in the normal range and the low T<sub>3</sub> syndrome was not shown in most patients. These findings support some previous studies and seemingly differ from others. Many confounding factors and study limitations, such as stroke severity, number of patients, thyroid hormone form (free or total), time of assessment, data analysis methods and neurological impairment scales, may have contributed to the difference in the results of these studies. Therefore, further larger and longitudinal studies with precise methodology and proper data analysis techniques are needed to find consistent results on the association between thyroid hormones and neurological impairments and to confirm our findings. Regarding the changes in thyroid hormones following stroke and the possible association between thyroid hormones and neurological deficits, monitoring thyroid status in stroke patients during consecutive days may be recommendable.</p></sec><sec id="sec8"><title>CRediT authorship contribution statement</title><p id="p0150"><bold>Kobra Akhoundzadeh:</bold> Writing &#x02013; original draft, Conceptualization. <bold>Ashraf Zarvani:</bold> Investigation. <bold>Fatemeh Mohajerani:</bold> Methodology. <bold>Sakineh Shafia:</bold> Supervision.</p></sec><sec id="sec9"><title>Ethics approval and consent to participate</title><p id="p0155">This work approved by Iran National Committee for Ethics in Biomedical Research (record no. IR.MAZUMS.REC.1398.1098, IR.MAZUMS.REC.1398.39, IR.MAZUMS.REC.1397.3291, IR.MAZUMS.REC.1398.6078) was supported by <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004160</institution-id><institution>Mazandaran University of Medical Sciences</institution></institution-wrap></funding-source>, Sari, Iran. Informed consent was obtained from all subjects and/or their legal guardian(s)</p></sec><sec id="sec10"><title>Consent for publication</title><p id="p0160">Not applicable.</p></sec><sec id="sec11"><title>Availability of data and materials&#x02019; statement</title><p id="p0165">The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.</p></sec><sec id="sec12"><title>Funding</title><p id="p0170">This work was supported by grants from the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004160</institution-id><institution>Mazandaran University of Medical Sciences</institution></institution-wrap></funding-source>, Sari, Iran, record no: 3291, 6078.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0175">I hereby declare that I have no pecuniary or other personal interest, direct or indirect, in any matter that raises or may raise any conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Feigin</surname><given-names>V.L.</given-names></name><name><surname>Krishnamurthi</surname><given-names>R.V.</given-names></name><name><surname>Parmar</surname><given-names>P.</given-names></name><name><surname>Norrving</surname><given-names>B.</given-names></name><name><surname>Mensah</surname><given-names>G.A.</given-names></name><name><surname>Bennett</surname><given-names>D.A.</given-names></name><name><surname>Barker-Collo</surname><given-names>S.</given-names></name><name><surname>Moran</surname><given-names>A.E.</given-names></name><name><surname>Sacco</surname><given-names>R.L.</given-names></name><name><surname>Truelsen</surname><given-names>T.</given-names></name></person-group><article-title>Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study</article-title><source>Neuroepidemiology</source><volume>45</volume><year>2015</year><fpage>161</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">26505981</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Xing</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>DU</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Prognostic value of thyroid hormones in acute ischemic stroke&#x02013;a meta analysis</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">28127051</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Dhital</surname><given-names>R.</given-names></name><name><surname>Poudel</surname><given-names>D.R.</given-names></name><name><surname>Tachamo</surname><given-names>N.</given-names></name><name><surname>Gyawali</surname><given-names>B.</given-names></name><name><surname>Basnet</surname><given-names>S.</given-names></name><name><surname>Shrestha</surname><given-names>P.</given-names></name><name><surname>Karmacharya</surname><given-names>P.</given-names></name></person-group><article-title>Ischemic stroke and impact of thyroid profile at presentation: a systematic review and meta-analysis of observational studies</article-title><source>J. Stroke Cerebrovasc. Dis.</source><volume>26</volume><year>2017</year><fpage>2926</fpage><lpage>2934</lpage><pub-id pub-id-type="pmid">28821377</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Lamba</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zaidi</surname><given-names>H.</given-names></name><name><surname>Broekman</surname><given-names>M.L.</given-names></name><name><surname>Simjian</surname><given-names>T.</given-names></name><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Doucette</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>T.R.</given-names></name><name><surname>Mekary</surname><given-names>R.A.</given-names></name></person-group><article-title>A prognostic role for low tri-iodothyronine syndrome in acute stroke patients: a systematic review and meta-analysis</article-title><source>Clin. Neurol. Neurosurg.</source><volume>169</volume><year>2018</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29627642</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>M.H.</given-names></name><name><surname>Beckett</surname><given-names>G.J.</given-names></name></person-group><article-title>Mechanisms behind the non-thyroidal illness syndrome: an update</article-title><source>J. Endocrinol.</source><volume>205</volume><year>2010</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">20016054</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Correlation analysis of serum thyroid stimulating hormone with acute cerebrovascular disease</article-title><source>Eur. J. Med. Res.</source><volume>24</volume><year>2019</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30606260</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Bunevicius</surname><given-names>A.</given-names></name><name><surname>Iervasi</surname><given-names>G.</given-names></name><name><surname>Bunevicius</surname><given-names>R.</given-names></name></person-group><article-title>Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders</article-title><source>Expert Rev. Neurother.</source><volume>15</volume><year>2015</year><fpage>315</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">25673072</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Pande</surname><given-names>A.</given-names></name><name><surname>Goel</surname><given-names>V.K.</given-names></name><name><surname>Rastogi</surname><given-names>A.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name></person-group><article-title>Thyroid dysfunction in patients of ischemic cerebrovascular accidents</article-title><source>Thyroid Res. Pract.</source><volume>14</volume><year>2017</year><fpage>32</fpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Low triiodothyronine: a new facet of inflammation in acute ischemic stroke</article-title><source>Clin. Chim. Acta</source><volume>458</volume><year>2016</year><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">27112304</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Leonards</surname><given-names>C.O.</given-names></name><name><surname>Schneider</surname><given-names>H.J.</given-names></name><name><surname>Liman</surname><given-names>T.G.</given-names></name><name><surname>Fiebach</surname><given-names>J.B.</given-names></name><name><surname>Endres</surname><given-names>M.</given-names></name><name><surname>Ebinger</surname><given-names>M.</given-names></name></person-group><article-title>Thyroid-stimulating hormone, white matter hyperintensities, and functional outcome in acute ischemic stroke patients</article-title><source>Cerebrovasc. Dis. Extra</source><volume>4</volume><year>2014</year><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">24803914</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Hama</surname><given-names>S.</given-names></name><name><surname>Kitaoka</surname><given-names>T.</given-names></name><name><surname>Shigenobu</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>Imura</surname><given-names>I.</given-names></name><name><surname>Seno</surname><given-names>H.</given-names></name><name><surname>Tominaga</surname><given-names>A.</given-names></name><name><surname>Arita</surname><given-names>K.</given-names></name><name><surname>Kurisu</surname><given-names>K.</given-names></name></person-group><article-title>Malnutrition and nonthyroidal illness syndrome after stroke</article-title><source>Metab., Clin. Exp.</source><volume>54</volume><year>2005</year><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">15931602</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Shulga</surname><given-names>A.</given-names></name><name><surname>Rivera</surname><given-names>C.</given-names></name></person-group><article-title>Interplay between thyroxin, BDNF and GABA in injured neurons</article-title><source>Neuroscience</source><volume>239</volume><year>2013</year><fpage>241</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">23246615</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Tu</surname><given-names>D.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name></person-group><article-title>Thyroxin treatment protects against white matter injury in the immature brain via brain-derived neurotrophic factor</article-title><source>Stroke</source><volume>44</volume><year>2013</year><fpage>2275</fpage><lpage>2283</lpage><pub-id pub-id-type="pmid">23715956</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>T.</given-names></name><name><surname>Impellizzeri</surname><given-names>D.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Cornelius</surname><given-names>C.</given-names></name><name><surname>Campolo</surname><given-names>M.</given-names></name><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name><name><surname>Esposito</surname><given-names>E.</given-names></name></person-group><article-title>Post-ischaemic thyroid hormone treatment in a rat model of acute stroke</article-title><source>Brain Res.</source><volume>1513</volume><year>2013</year><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">23500636</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Sabbaghziarani</surname><given-names>F.</given-names></name><name><surname>Mortezaee</surname><given-names>K.</given-names></name><name><surname>Akbari</surname><given-names>M.</given-names></name><name><surname>Kashani</surname><given-names>I.R.</given-names></name><name><surname>Soleimani</surname><given-names>M.</given-names></name><name><surname>Hassanzadeh</surname><given-names>G.</given-names></name><name><surname>Zendedel</surname><given-names>A.</given-names></name></person-group><article-title>Stimulation of neurotrophic factors and inhibition of proinflammatory cytokines by exogenous application of triiodothyronine in the rat model of ischemic stroke</article-title><source>Cell Biochem. Funct.</source><volume>35</volume><year>2017</year><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">28083964</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Sadana</surname><given-names>P.</given-names></name><name><surname>Coughlin</surname><given-names>L.</given-names></name><name><surname>Burke</surname><given-names>J.</given-names></name><name><surname>Woods</surname><given-names>R.</given-names></name><name><surname>Mdzinarishvili</surname><given-names>A.</given-names></name></person-group><article-title>Anti-edema action of thyroid hormone in MCAO model of ischemic brain stroke: possible association with AQP4 modulation</article-title><source>J. Neurol. Sci.</source><volume>354</volume><year>2015</year><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">25963308</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Mokhtari</surname><given-names>T.</given-names></name><name><surname>Akbari</surname><given-names>M.</given-names></name><name><surname>Malek</surname><given-names>F.</given-names></name><name><surname>Kashani</surname><given-names>I.R.</given-names></name><name><surname>Rastegar</surname><given-names>T.</given-names></name><name><surname>Noorbakhsh</surname><given-names>F.</given-names></name><name><surname>Ghazi-Khansari</surname><given-names>M.</given-names></name><name><surname>Attari</surname><given-names>F.</given-names></name><name><surname>Hassanzadeh</surname><given-names>G.</given-names></name></person-group><article-title>Improvement of memory and learning by intracerebroventricular microinjection of T3 in rat model of ischemic brain stroke mediated by upregulation of BDNF and GDNF in CA1 hippocampal region</article-title><source>Daru</source><volume>25</volume><year>2017</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">28088246</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Rastogi</surname><given-names>L.</given-names></name><name><surname>Godbole</surname><given-names>M.M.</given-names></name><name><surname>Ray</surname><given-names>M.</given-names></name><name><surname>Rathore</surname><given-names>P.</given-names></name><name><surname>Pradhan</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S.K.</given-names></name><name><surname>Pandey</surname><given-names>C.M.</given-names></name></person-group><article-title>Reduction in oxidative stress and cell death explains hypothyroidism induced neuroprotection subsequent to ischemia/reperfusion insult</article-title><source>Exp. Neurol.</source><volume>200</volume><year>2006</year><fpage>290</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">16616921</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Shuaib</surname><given-names>A.</given-names></name><name><surname>Ijaz</surname><given-names>S.</given-names></name><name><surname>Mazagri</surname><given-names>R.</given-names></name><name><surname>Kalra</surname><given-names>J.</given-names></name><name><surname>Hemmings</surname><given-names>S.</given-names></name><name><surname>Senthilsvlvan</surname><given-names>A.</given-names></name><name><surname>Crosby</surname><given-names>N.</given-names></name></person-group><article-title>Hypothyroidism protects the brain during transient forebrain ischemia in gerbils</article-title><source>Exp. Neurol.</source><volume>127</volume><year>1994</year><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">7911086</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Shuaib</surname><given-names>A.</given-names></name><name><surname>Ijaz</surname><given-names>S.</given-names></name><name><surname>Hemmings</surname><given-names>S.</given-names></name><name><surname>Galazka</surname><given-names>P.</given-names></name><name><surname>Ishaqzay</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Ravindran</surname><given-names>J.</given-names></name><name><surname>Miyashita</surname><given-names>H.</given-names></name></person-group><article-title>Decreased glutamate release during hypothyroidism may contribute to protection in cerebral ischemia</article-title><source>Exp. Neurol.</source><volume>128</volume><year>1994</year><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">7915676</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="book" id="sref21"><person-group person-group-type="author"><name><surname>Delong</surname><given-names>J.H.</given-names></name><name><surname>Ohashi</surname><given-names>S.N.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>K.C.</given-names></name><name><surname>Sansing</surname><given-names>L.H.</given-names></name></person-group><part-title>Inflammatory responses after ischemic stroke</part-title><source>Seminars in Immunopathology</source><year>2022</year><publisher-name>Springer</publisher-name><fpage>625</fpage><lpage>648</lpage></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>K.N.</given-names></name><name><surname>Elm</surname><given-names>J.J.</given-names></name><name><surname>Molyneaux</surname><given-names>B.J.</given-names></name><name><surname>Hinson</surname><given-names>H.</given-names></name><name><surname>Beslow</surname><given-names>L.A.</given-names></name><name><surname>Sze</surname><given-names>G.K.</given-names></name><name><surname>Ostwaldt</surname><given-names>A.-C.</given-names></name><name><surname>Del Zoppo</surname><given-names>G.J.</given-names></name><name><surname>Simard</surname><given-names>J.M.</given-names></name><name><surname>Jacobson</surname><given-names>S.</given-names></name></person-group><article-title>Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial</article-title><source>Lancet Neurol.</source><volume>15</volume><year>2016</year><fpage>1160</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">27567243</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name></person-group><article-title>Low tri-iodothyronine syndrome is associated with cognitive impairment in patients with acute ischemic stroke: a prospective cohort study</article-title><source>Am. J. Geriatr. Psychiatr.</source><volume>26</volume><year>2018</year><fpage>1222</fpage><lpage>1230</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Bao</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Low T3 levels as a predictor marker predict the prognosis of patients with acute ischemic stroke</article-title><source>Int. J. Neurosci.</source><volume>127</volume><year>2017</year><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">27401927</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Meyer</surname><given-names>M.A.</given-names></name></person-group><article-title>Clinical analysis on alteration of thyroid hormones in the serum of patients with acute ischemic stroke</article-title><source>Stroke Res. Treat.</source><volume>2010</volume><year>2010</year></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Sidorov</surname><given-names>E.</given-names></name><name><surname>Paul</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Delpirou Nouh</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Gosmanova</surname><given-names>A.</given-names></name><name><surname>Gosmanov</surname><given-names>N.</given-names></name><name><surname>Gordon</surname><given-names>D.L.</given-names></name><name><surname>Baranskaya</surname><given-names>I.</given-names></name><name><surname>Chainakul</surname><given-names>J.</given-names></name><name><surname>Hamilton</surname><given-names>R.</given-names></name><name><surname>Mdzinarishvili</surname><given-names>A.</given-names></name></person-group><article-title>Change of thyroid function after ischemic stroke and its relation to stroke severity</article-title><source>European Stroke Journal</source><volume>7</volume><year>2022</year><fpage>436</fpage></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Filimonov</surname><given-names>D.</given-names></name><name><surname>Yevtushenko</surname><given-names>S.</given-names></name><name><surname>Yeresko</surname><given-names>A.</given-names></name><name><surname>Fedorova</surname><given-names>A.</given-names></name><name><surname>Trubnikova</surname><given-names>N.</given-names></name><name><surname>Belotserkovskaya</surname><given-names>M.</given-names></name></person-group><article-title>Impact of serum triiodothyronine on neurological deficit and outcome in acute ischemic stroke and possible in-vivo neuroprotective effects of its novel derivate-thyronamine</article-title><source>Int. J. Stroke</source><volume>15</volume><year>2020</year><fpage>426</fpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Suda</surname><given-names>S.</given-names></name><name><surname>Muraga</surname><given-names>K.</given-names></name><name><surname>Kanamaru</surname><given-names>T.</given-names></name><name><surname>Okubo</surname><given-names>S.</given-names></name><name><surname>Abe</surname><given-names>A.</given-names></name><name><surname>Aoki</surname><given-names>J.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Sakamoto</surname><given-names>Y.</given-names></name><name><surname>Shimoyama</surname><given-names>T.</given-names></name><name><surname>Nito</surname><given-names>C.</given-names></name><name><surname>Kimura</surname><given-names>K.</given-names></name></person-group><article-title>Low free triiodothyronine predicts poor functional outcome after acute ischemic stroke</article-title><source>J. Neurol. Sci.</source><volume>368</volume><year>2016</year><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">27538607</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Forti</surname><given-names>P.</given-names></name><name><surname>Maioli</surname><given-names>F.</given-names></name><name><surname>Coveri</surname><given-names>M.</given-names></name><name><surname>Nativio</surname><given-names>V.</given-names></name><name><surname>Arnone</surname><given-names>G.</given-names></name><name><surname>Loreti</surname><given-names>A.</given-names></name><name><surname>Zoli</surname><given-names>M.</given-names></name></person-group><article-title>Thyroid function tests and early outcomes of acute ischemic stroke in older euthyroid patients</article-title><source>Exp. Gerontol.</source><volume>61</volume><year>2015</year><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">25449856</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>O &#x02019; Keefe</surname><given-names>L.M.</given-names></name><name><surname>Conway</surname><given-names>S.E.</given-names></name><name><surname>Czap</surname><given-names>A.</given-names></name><name><surname>Malchoff</surname><given-names>C.D.</given-names></name><name><surname>Benashski</surname><given-names>S.</given-names></name><name><surname>Fortunato</surname><given-names>G.</given-names></name><name><surname>Staff</surname><given-names>I.</given-names></name><name><surname>Mccullough</surname><given-names>L.D.</given-names></name></person-group><article-title>Thyroid hormones and functional outcomes after ischemic stroke</article-title><source>Thyroid Res.</source><volume>8</volume><year>2015</year><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">25878727</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Akhoundi</surname><given-names>F.</given-names></name><name><surname>Ghorbani</surname><given-names>A.</given-names></name><name><surname>Soltani</surname><given-names>A.</given-names></name><name><surname>Meysamie</surname><given-names>A.</given-names></name></person-group><article-title>Favorable functional outcomes in acute ischemic stroke patients with subclinical hypothyroidism</article-title><source>Neurology</source><volume>77</volume><year>2011</year><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">21715712</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>J.</given-names></name><name><surname>Chung</surname><given-names>P.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Moon</surname><given-names>H.</given-names></name><name><surname>Suh</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>D.</given-names></name><name><surname>AL</surname><given-names>E.</given-names></name></person-group><article-title>Favorable influence of subclinical hypothyroidism on the functional outcomes in stroke patients</article-title><source>Endocr. J.</source><volume>57</volume><year>2010</year><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">19823001</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.Y.</given-names></name><name><surname>Li</surname><given-names>W.Y.</given-names></name><name><surname>Hu</surname><given-names>X.Y.</given-names></name></person-group><article-title>Alteration of thyroid-related hormones within normal ranges and early functional outcomes in patients with acute ischemic stroke</article-title><source>International Journal of Endocrinology</source><volume>2016</volume><year>2016</year></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>W.-Y.</given-names></name><name><surname>Mei</surname><given-names>H.-N.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name></person-group><article-title>Repetitive transcranial magnetic stimulation (rTMS) modulates thyroid hormones level and cognition in the recovery stage of stroke patients with cognitive dysfunction</article-title><source>Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.: International Medical Journal of Experimental and Clinical Research</source><volume>27</volume><year>2021</year><object-id pub-id-type="publisher-id">e931914</object-id><comment>1</comment></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>M.</given-names></name><name><surname>Fang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Low free triiodothyronine levels predict symptomatic intracranial hemorrhage and worse short-term outcome of thrombolysis in patients with acute ischemia stroke</article-title><source>Medicine (United States)</source><volume>96</volume><year>2017</year></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Si</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Qiao</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name></person-group><article-title>Low free triiodothyronineis predicts worsen neurological outcome of patients with acute ischemic stroke: a retrospective study with bioinformatics analysis</article-title><source>BMC Neurol.</source><volume>19</volume><year>2019</year></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Suda</surname><given-names>S.</given-names></name><name><surname>Shimoyama</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>K.</given-names></name><name><surname>Arakawa</surname><given-names>M.</given-names></name><name><surname>Aoki</surname><given-names>J.</given-names></name><name><surname>Kanamaru</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Sakamoto</surname><given-names>Y.</given-names></name><name><surname>Takeshi</surname><given-names>Y.</given-names></name><name><surname>Matsumoto</surname><given-names>N.</given-names></name><name><surname>Nishiyama</surname><given-names>Y.</given-names></name><name><surname>Nito</surname><given-names>C.</given-names></name><name><surname>Mishina</surname><given-names>M.</given-names></name><name><surname>Kimura</surname><given-names>K.</given-names></name></person-group><article-title>Low free triiodothyronine predicts 3-month poor outcome after acute stroke</article-title><source>J. Stroke Cerebrovasc. Dis.</source><volume>27</volume><year>2018</year><fpage>2804</fpage><lpage>2809</lpage><pub-id pub-id-type="pmid">30056971</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Bunevicius</surname><given-names>A.</given-names></name><name><surname>Kazlauskas</surname><given-names>H.</given-names></name><name><surname>Raskauskiene</surname><given-names>N.</given-names></name><name><surname>Janusonis</surname><given-names>V.</given-names></name><name><surname>Bunevicius</surname><given-names>R.</given-names></name></person-group><article-title>Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study</article-title><source>Endocrine</source><volume>45</volume><year>2014</year><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">23605905</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.-H.</given-names></name><name><surname>Zhuang</surname><given-names>J.-H.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Y.-X.</given-names></name><name><surname>Zhao</surname><given-names>Y.-C.</given-names></name><name><surname>Ma</surname><given-names>Y.-J.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name></person-group><article-title>Relationship between &#x003b2;-amyloid protein 1-42, thyroid hormone levels and the risk of cognitive impairment after ischemic stroke</article-title><source>World Journal of Clinical Cases</source><volume>8</volume><year>2020</year><fpage>76</fpage><pub-id pub-id-type="pmid">31970172</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Murolo</surname><given-names>M.</given-names></name><name><surname>DI Vincenzo</surname><given-names>O.</given-names></name><name><surname>Cicatiello</surname><given-names>A.G.</given-names></name><name><surname>Scalfi</surname><given-names>L.</given-names></name><name><surname>Dentice</surname><given-names>M.</given-names></name></person-group><article-title>Cardiovascular and neuronal consequences of thyroid hormones alterations in the ischemic stroke</article-title><source>Metabolites</source><volume>13</volume><year>2022</year><fpage>22</fpage><pub-id pub-id-type="pmid">36676947</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Shipton</surname><given-names>D.</given-names></name><name><surname>Tappin</surname><given-names>D.M.</given-names></name><name><surname>Vadiveloo</surname><given-names>T.</given-names></name><name><surname>Crossley</surname><given-names>J.A.</given-names></name><name><surname>Aitken</surname><given-names>D.A.</given-names></name><name><surname>Chalmers</surname><given-names>J.</given-names></name></person-group><article-title>Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study</article-title><source>Bmj</source><volume>339</volume><year>2009</year></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Sangari</surname><given-names>A.</given-names></name><name><surname>Akhoundzadeh</surname><given-names>K.</given-names></name><name><surname>Vahedian</surname><given-names>M.</given-names></name><name><surname>Sharifipour</surname><given-names>E.</given-names></name></person-group><article-title>Effect of pre-hospital notification on delays and neurological outcomes in acute ischemic stroke</article-title><source>Australasian Emergency Care</source><volume>25</volume><year>2022</year><fpage>172</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">34810150</pub-id>
</element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgment</title><p id="p0180">The authors would like to thank Mazandaran University of Medical Sciences, Sari, Iran for providing facilities for this work. This paper was financially supported by Vice Chancellor for Research Centers of <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004160</institution-id><institution>Mazandaran University of Medical Sciences</institution></institution-wrap></funding-source>, Sari, Iran (Grant Number: 3291, 6078).</p></ack></back></article>